Furthering our understanding of fluorescent probes like NBDM will expedite the development of Glut5-specific PET compounds which could be non-invasive tools for determining Glut5 expression in vivo and provide a means for monitoring the onset and progression of metabolic syndrome and aggressive cancers. Here, SLC2A5 is linked to metabolic syndrome.